S3-Leitlinie „Interdisziplinäre Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms“
Tóm tắt
Từ khóa
Tài liệu tham khảo
Caumo F et al (2014) Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. Breast 23(1):76–80
Lang K et al (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26(1):184–190
Skaane P et al (2014) Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3):655–663
Hahnen E et al (2017) Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 3(10):1378–1385
Liu M et al (2013) Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett 5(3):983–991
Moran MS et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32(14):1507–1515
Lyman GH, Somerfield MR, Giuliano AE (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract 13(3):196–198
McCormick B et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747
Department of Health (2015) National Clinical Guideline—Diagnosis, staging and treatment of patients with breast cancer. National Clinical Guideline No. 7
Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784
Eisen A, Fletcher GG, Gandhi S et al (2014) Optimal systemic therapy for early female breast Cancer. Evidence-based series, S 1–21
Aebi S et al (2014) Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 15(2):156–163
Finn RS et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35
Hortobagyi GN et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748
Runowicz CD et al (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34(6):611–635
Wöckel A et al (2018) Früherkennung, Diagnostik, Therapie und Nachsorge des primären Mammakarzinoms. Dtsch Arztebl Int 115(18):316–323. https://doi.org/10.3238/arztebl.2018.0316